Inovio Pharmaceuticals (INO) Accounts Payables (2010 - 2026)

Inovio Pharmaceuticals has disclosed Accounts Payables across 17 years of filings, most recently posting $11.7 million for Q2 2026.

• In Q2 2026, Accounts Payables fell 26.01% year-over-year to $11.7 million; the TTM figure through Jun 2026 stood at $11.7 million (down 26.01% YoY), while the FY2025 annual figure was $11.1 million, down 31.77% from the prior year.
• Accounts Payables came in at $11.7 million for Q2 2026 at Inovio Pharmaceuticals, up from $9.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $105.0 million in Q2 2022 to a low of $9.3 million in Q1 2026.
• Average Accounts Payables over 5 years is $28.8 million, with a median of $16.4 million recorded in 2024.
• Year-over-year, Accounts Payables jumped 248.94% in 2022 and slumped 79.75% in 2023.
• Over 5 years, Accounts Payables stood at $79.7 million in 2022, then sank by 75.09% to $19.8 million in 2023, then retreated by 18.38% to $16.2 million in 2024, then plunged by 31.77% to $11.1 million in 2025, then increased by 5.42% to $11.7 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $11.7 million in Q2 2026, $9.3 million in Q1 2026, and $11.1 million in Q4 2025.